检索结果-南通市图书馆

transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma

引用

World Journal of Gastrointestinal Oncology 2025年第1期17卷 52-61页

作者： Fei-Da Wu Hai-Feng Zhou Wei Yang Di Zhu Bi-Fei Wu Hai-Bin Shi Sheng Liu Wei-Zhong Zhou Department of Interventional Radiology The First Affiliated Hospital of Nanjing Medical UniversityNanjing 210029Jiangsu ProvinceChina

BACKGROUND Hepatocellular carcinoma(HCC)is the most common form of liver cancer that has limited treatment options and a poor *** chemoembolization(TACE)is the first-line treatment for intermediate-stage HCC but can induce tumour hypoxia,thereby promoting *** studies suggested that combining TACE with anti-angiogenic therapies and immunotherapy might im-prove ***,a tyrosine kinase inhibitor,has demonstrated superior outcomes compared to sorafenib,while immune checkpoint inhibitors such as sintilimab show potential when combined with ***,the efficacy and safety of TACE combined with lenvatinib and sintilimab(TACE+SL)compared to TACE with lenvatinib alone(TACE+L)in patients with intermediate-ad-vanced HCC has not yet been *** To evaluate the efficacy and safety of TACE+SL therapy in comparison to TACE+L therapy in patients with intermediate-advanced *** A retrospective analysis was performed on patients with intermediate-advanced HCC who received TACE plus lenvatinib with or without sintilimab between September 2019 and September *** characteristics were compared,and propensity score matching was *** survival(OS),progression-free survival(PFS),and objective response rate(ORR)were evaluated between the two groups,and adverse events were *** The study included 57 patients,with 30 in the TACE+SL group and 27 in the TACE+L *** TACE+SL group demonstrated significantly improved median PFS and OS compared to the TACE+L group(PFS:14.1 months vs 9.6 months,P=0.016;OS:22.4 months vs 14.1 months,P=0.039),along with a higher ORR(70.0%vs 55.6%).After propensity score matching,30 patients were included,with the TACE+SL group again showing longer median PFS and a trend toward improved OS(PFS:14.6 months vs 9.2 months,P=0.012;OS:23.9 months vs 16.3 months,P=0.063),and a higher ORR(73.3%vs 53.3%).No severe adverse events were *** TACE+SL demonstrat

关键词： Hepatocellular carcinoma transarterial chemoembolization Sintilimab Lenvatinib Immunotherapy Programmed cell death 1 Prognosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China

引用

World Journal of Gastroenterology 2010年第2期16卷 264-269页

作者： Shi, Ming Chen, Ji-An Lin, Xiao-Jun Guo, Rong-Ping Yuan, Yun-Fei Chen, Min-Shan Zhang, Ya-Qi Li, Jin-Qing Sun Yat Sen Univ Dept Hepatobiliary Ctr Canc Guangzhou 510060 Guangdong Peoples R China

AIM:To identify prognostic factors from pretreatment variables of the initial transarterial chemoembolization(TACE)procedure in unresectable hepatocellular carcinoma(HCC). METHODS:One thousand and five hundred and sixtynine patients with unresectable HCC underwent TACE as initial treatment were retrospectively *** variables of the initial TACE procedure with a P value less than 0.05 by univariate analysis were subjected to Cox proportional hazards model. RESULTS:The median overall survival time and 1-, 5-,10-year survival rates were 10.37 mo,47%,10%, and 7%,respectively.A Cox proportional hazard model showed that 8 pretreatment factors of regional lymphnodes metastasis,Child-Pugh class,macrovascular invasion,greatest dimension,α-fetoprotein(AFP), Hepatitis virus B,tumor capsule,and nodules were independent prognostic *** with multimodality therapy have better survival than those with TACE treatment only. CONCLUSION:Tumor status,hepatic function reserve,AFP,and hepatitis virus B status were independent prognostic factors for unresectable *** metastasis might not be a contraindication to TACE. Multimodality therapy might improve survival.

关键词： Hepatocellular carcinoma transarterial chemoembolization Palliative treatment Prognosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma

引用

World Journal of Gastroenterology 2016年第40期22卷 8853-8861页

作者： Hee Chul Nam Bohyun Jang Myeong Jun Song Department of Internal Medicine College of Medicine the Catholic University of Korea Division of Hepatology Department of Internal Medicine Daejeon St. Mary’s Hospital College of Medicine The Catholic University of Korea

transarterial chemoembolization(TACE) is a widely used standard treatment for patients with hepatocellular carcinoma(HCC) who are not suitable candidates for curative treatments. The rationale for TACE is that intra-arterial chemotherapy using lipiodol and chemotherapeutic agents, followed by selective vascular embolization, results in a strong cytotoxic effect as well as ischemia(conventional TACE). Recently, drugeluting beads(DC Beads?) have been developed for transcatheter treatment of HCC to deliver higher doses of the chemotherapeutic agent and to prolong contact time with the tumor. DC Beads? can actively sequester doxorubicin hydrochloride from solution and release it in a controlled sustained fashion. Treatment with DC Beads? substantially reduced the amount of chemotherapeutic agent that reached the systemic circulation compared with conventional, lipiodol-based regimens, significantly reducing drug-related adverse events. In this article, we describe the treatment response, survival, and safety of TACE used with drugeluting beads for the treatment of HCC and discuss future therapeutic possibilities.

关键词： Hepatocellular carcinoma transarterial chemoembolization Conventional TACE Drug-eluting beads Treatment response

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma

引用

World Journal of Gastroenterology 2020年第27期26卷 3975-3988页

作者： Jian-Hai Guo Shao-Xing Liu Song Gao Fu-Xin Kou Xin Zhang Di Wu Xiao-Ting Li Hui Chen Xiao-Dong Wang Peng Liu Peng-Jun Zhang Hai-Feng Xu Guang Cao Lin-Zhong Zhu Ren-Jie Yang Xu Zhu Department of Interventional Therapy Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital and InstituteBeijing 100142China Department of Radiology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital and InstituteBeijing 100142China

BACKGROUND transarterial chemoembolization(TACE)and hepatic arterial infusion chemotherapy(HAIC)have shown promising local benefits for advanced hepatocellular carcinoma(HCC).S-1,a composite preparation of a 5-fluorouracil prodrug,has proven to be a convenient oral chemotherapeutic agent with definite efficacy against advanced *** To evaluate the efficacy and safety of TACE followed by HAIC with or without oral S-1 for treating advanced *** In this single-center,open-label,prospective,randomized controlled trial,117 participants with advanced HCC were randomized to receive TACE followed by oxaliplatin-based HAIC either with(TACE/HAIC+S-1,n=56)or without(TACE/HAIC,n=61)oral S-1 between December 2013 and September *** participants were excluded from final analysis for withdrawing *** primary endpoint was progression-free survival(PFS)and secondary endpoints included overall survival(OS),objective response rate,disease control rate and *** In total,115 participants(100 males and 15 females;mean age,57.7 years±11.9)were *** median PFS and OS were 5.0 mo(0.4–58.6 mo)(95%confidence interval(CI):3.82 to 6.18)vs 4.4 mo(1.1–54.4 mo)(95%CI:2.54 to 6.26;P=0.585)and 8.4 mo(0.4–58.6 mo)(95%CI:6.88 to 9.92)vs 8.3 mo(1.4–54.4 m)(95%CI:5.71 to 10.96;P=0.985)in the TACE/HAIC+S-1 and TACE/HAIC groups,*** objective response rate and disease control rate were 30.9%vs 18.4%and 72.7%vs 56.7%in the TACE/HAIC+S-1 and TACE/HAIC groups,*** 3/4 adverse events had a similar frequency in both treatment *** No improvements in tumor response rates,PFS or OS were observed with the addition of S-1 to TACE/HAIC in advanced *** treatment regimens had a similar safety profile.

关键词： Hepatocellular carcinoma Advanced Hepatic arterial infusion chemotherapy transarterial chemoembolization Prognosis Efficacy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

transarterial chemoembolization and bland embolization for hepatocellular carcinoma

引用

World Journal of Gastroenterology 2014年第12期20卷 3069-3077页

作者： Emmanuel A Tsochatzis Evangelia Fatourou James O'Beirne Tim Meyer Andrew K Burroughs Sheila Sherlock Liver Centre Royal Free Hospital and UCL Institute of Liver and Digestive Health Department of Oncology Royal Free Hospital and UCL

transarterial chemoembolization(TACE)is the first line treatment for patients with intermediate stage hepatocellular carcinoma but is also increasingly being used for patients on the transplant waiting list to prevent further tumor *** its widespread use,TACE remains an unstandardized procedure,with variation in type and size of embolizing particles,type and dose of chemotherapy and interval between *** evidence from randomized controlled trials suggest that bland transarterial embolization(TAE)has the same efficacy with *** the current article,we review the use of TACE and TAE for hepatocellular carcinoma and we focus on the evidence for their use.

关键词： Cirrhosis Hepatocellular carcinoma Mortality Embolization transarterial chemoembolization transarterial embolization Prognosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival

引用

Hepatobiliary & Pancreatic Diseases International 2007年第3期6卷 259-266页

作者： Timm D Kirchhoff Joerg S Bleck Arne Dettmer Ajay Chavan Herbert Rosenthal Sonja Merkesdal Bernd Frericks Lars Zender Nisar P Malek Tim F Greten Stefan Kubicka Michael P Manns Michael Galanski Department of Diagnostic Radiology Hannover Medical School Germany Department of Gastroenterology Hepatology and Endocrinology Hannover Medical School Germany Department of Diagnostic and Interventional Radiology Klinikum Oldenburg Germany Division of Rheumatology Hannover Medical School Germany Department of Radiology and Nuclear Medicine Campus B.F-Charité-University Medicine Berlin Germany

BACKGROUND: In a multidisciplinary conference patients with advanced non-resectable hepatocellular carcinoma (HCC) were stratified according to their clinical status and tumor extent to different regional modalities or to best supportive care. The present study evaluated all patients who were stratified to repeated transarterial chemoembolization (TACE) from 1999 until 2003 in terms of tumor response, toxicity, and survival. A moderate embolizing approach was chosen using a combination of degradable starch microspheres (DSM) and iodized oil (Lipiodol) in order to combine anti-tumoral efficiency and low toxicity. METHODS: Fourty-seven patients were followed up prospectively. TACE treatment consisted of cisplatin (50 mg/m2), doxorubicin (50 mg/m2), 450-900 mg DSM, and 5-30 ml Lipiodol. DSM and Lipiodol were administered according to tumor vascularization. Patient characteristics,toxicity, and complications were outlined. In multivariate regression analyses of pre-treatment variables from a prospective database, predictors for tumor response and survival after TACE were determined. RESULTS: 112 TACE courses were performed (2.4±1.5 courses per patient). Mean maximum tumor size was 75 (± 43) mm, in 68% there was bilobar disease. Best response to TACE treatment was: progressive disease (PD) 9%, stable disease (SD) 55%, partial remission (PR) 36%, and complete remission (CR) 0%. Multivariate regression analyses identified tumor size ≤75 mm, tumor number ≤5, and tumor hypervascularization as predictors for PR. The overall 1-, 2-, and 3-year-survival rates were 75%, 59%, and 41%, respectively, and the median survival was 26 months. Low α-fetoprotein levels (30 months, R2=36%). Grade 3 toxicity occurred in 7.1% (n=8), and grade 4 toxicity in 3.6% (n=4) of all courses in terms of reversible leukopenia and thrombocytopenia. The incidence of major

关键词： carcinoma, hepatocellular transarterial chemoembolization degradable starch microspheres Lipiodol tumor response survival

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

transarterial chemoembolization combined with radiofrequency ablation in the treatment of large hepatocellular carcinoma with stage C

引用

World Journal of Clinical Cases 2022年第33期10卷 12156-12163页

作者： Sha-Sha Sun Wen-Dong Li Jing-Long Chen Department of Oncology Capital Medical University Affiliated Beijing Ditan HospitalBeijing 100015China

BACKGROUND The combination therapy of transarterial chemoembolization and radiofrequency ablation(TACE-RFA)shows promising efficacy in large hepatocellular carcinoma(HCC).Data on the clinical efficacy and safety of TACE-RFA for large HCC with barcelona clinic liver cancer(BCLC)stage C are lacking in *** To determine the safety and efficacy of TACE-RFA for large,advanced *** Patients of HCC with BCLC stage C who were treated with TACE-RFA or TACE alone at our institute from August 2008 to January 2017 were retrospectively *** complications were *** associations between overall survival(OS)and treatment method were *** Data were collected from 102 HCC *** them,64 underwent TACERFA and 38 underwent *** combination of TACE and RFA was *** complications were *** median OS in the TACE-RFA group was significantly longer than that in the TACE group(8.0 mo vs 4.0 mo,P=0.000).The 6-,12-and 24-mo survival rates of the combination group were 68.8%,34.4%,and 10.9%,respectively,while those of the TACE group were 36.8%,7.9%,and 0%(P<0.05).CONCLUSION TACE-RFA has an advantage over TACE alone in improving OS in large HCC patients with BCLC stage C.

关键词： Large advanced hepatocellular carcinoma transarterial chemoembolization Radiofrequency ablation Overall survival Combination therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

transarterial chemoembolization vs. liver resection as initial treatment for hepatocellular carcinoma occurring exclusively in caudate lobe: A retrospective propensity matching analysis

引用

Oncology Research 2022年第1期30卷 23-33页

作者： BIAO YANG MINLAN YUAN TING YANG ZHENGYIN LIAO HAO WU Department of Abdominal Oncology West China HospitalSichuan UniversityChengduChina Department of Psychiatry West China HospitalSichuan UniversityChengduChina Department of Gastroentology West China HospitalSichuan UniversityChengduChina

Treatment of hepatocellular carcinoma(HCC)in the caudate lobe is technically *** retrospective study was designed to evaluate the clinical outcome of both superselective transcatheter arterial chemoembolization(TACE)and liver resection(LR)for HCC occurring exclusively in the caudate *** January 2008 to September 2021,a total of 129 patients were diagnosed with HCC of the caudate *** Cox proportional hazard model was used to analyze the potential clinical factors and established prognostic nomograms with interval *** the total number of patients,78 received TACE and 51 received *** overall survival(OS)rates(TACE ***)at 1,2,3,4,and 5 years were 83.9%vs.71.0%;74.2%vs.61.3%;58.1%vs.48.4%;45.2%vs.45.2%;and 32.3%vs.25.0%,***,subgroup analysis revealed that TACE was superior to LR for treating patients with stage IIb Chinese liver cancer(CNLC-IIb)in the entire cohort(p=0.002).Interestingly,no difference was found between TACE and LR in the treatment outcomes of CNLC-IIa HCC(p=0.6).Based on Child-Pugh A and B calculations,TACE tended to lead to a better OS than LR(p=0.081 and 0.16,respectively).Multivariate analysis showed that Child-Pugh score,CNLC stage,ascites,alpha fetoprotein(AFP),tumor size,and anti-HCV are related to *** nomograms for 1,2,and 3 years were *** on this study,TACE may provide a longer OS than liver resection for patients with CNLC-IIb HCC of the caudate *** this suggestion is limited by the study design and relatively small sample size,additional randomized controlled trials are needed.

关键词： transarterial chemoembolization Liver resection Hepatocellular carcinoma Caudate lobe

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition

引用

World Journal of Gastrointestinal Surgery 2022年第6期14卷 528-537页

作者： Shen Zhang Bin-Yan Zhong Lei Zhang Wan-Sheng Wang Cai-Fang Ni Department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySuzhou 215006Jiangsu ProvinceChina

Multi-session transarterial chemoembolization(TACE)is usually needed for the treatment of intermediate-stage hepatocellular carcinoma(HCC),but it may not always have a positive influence on prognosis due to high heterogeneity of *** avoid ineffective repeated TACE,the concept of TACE failure/refractoriness has been proposed by several organizations and is being addressed using tyrosine kinase *** concept of TACE failure/refractoriness is controversial due to ambiguous definitions and low evidence-based *** date,only a few studies have examined the rationality concerning the definition of TACE failure/refractoriness,although the concept has been introduced and applied in many TACE-related clinical *** review focuses on some of the issues related to different versions of TACE failure/refractoriness,the rationality of related definitions,and the feasibility of continuing TACE after so-called failure/refractoriness based on published evidence.A suggestion to re-define TAEC failure/refractoriness is also put forward.

关键词： Hepatocellular carcinoma transarterial chemoembolization Failure Refractoriness

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular

引用

iLIVER 2022年第4期1卷 225-234页

作者： Jingxin Yan Manjun Deng Shunyu Kong Ting Li Zhenwu Lei Lushun Zhang Yutong Zhuang Xin He Huanwei Wang Haining Fan Yingxing Guo Department of Interventional Therapies Affiliated Hospital of Qinghai UniversityXiningChina Department of Postgraduate Qinghai UniversityXiningChina Department of Hepatopancreatobiliary Surgery Affiliated Hospital of Qinghai UniversityXiningChina Qinghai Province Key Laboratory of Hydatid Disease Research XiningChina Department of Orthopedics Sichuan Provincial People's HospitalChengduChina Department of Postgraduate Chengdu Medical CollegeChengduChina Department of Pathology and Pathophysiology Chengdu Medical CollegeChengduChina Center of Sichuan for Elderly Care and Health Chengdu Medical CollegeChengduChina Department of Neurosurgery The Second School of Clinical MedicineSouthern Medical UniversityGuangzhou 510515GuangdongChina

Hepatocellular carcinoma(HCC)is one of the most common malignancies *** the development of systemic therapies,several studies are currently underway,especially those related to the use of programmed death-1/programmed cell death-ligand 1(PD-1/PD-L1)***,studies on transarterial che-moembolization(TACE)and PD-1/PD-L1 immunotherapy have demonstrated some interesting *** article reviewed the current clinical evidence on the combination of TACE and PD-1/PD-L1 ***,our review summarized that a favorable survival time could be achieved using this combination in most ***,complications such as hyperprogression should be taken seriously,and the underlying mechanisms need to be explored.

关键词： Hepatocellular carcinoma transarterial chemoembolization Programmed death 1 Programmed cell death-ligand 1 Clinical evidence

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：